SPDB
目录号 : GC30150
SPDB是一个可以连接DM4的片段。
Cas No.:115088-06-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
SPDB is a small fragment that can linked DM4 conjugates. Conjugated to antibodies utilizing disulfide linkers: anti-EGFR-SPDB-DM4 has been widely used.
[1]. Widdison WC et al. Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolitesin Cancer Cells andInduce High Levels of Bystander Killing. Bioconjug Chem, 2015 Nov 18, 26(11):2261-78.
| Cas No. | 115088-06-7 | SDF | |
| Canonical SMILES | O=C(CC1)N(OC(CCCSSC2=NC=CC=C2)=O)C1=O | ||
| 分子式 | C13H14N2O4S2 | 分子量 | 326.39 |
| 溶解度 | Ethanol: 100 mg/mL (306.38 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0638 mL | 15.3191 mL | 30.6382 mL |
| 5 mM | 0.6128 mL | 3.0638 mL | 6.1276 mL |
| 10 mM | 0.3064 mL | 1.5319 mL | 3.0638 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
SPdb--a signal peptide database
BMC Bioinformatics 2005 Oct 13;6:249.16221310 PMC1276010
Background: The signal peptide plays an important role in protein targeting and protein translocation in both prokaryotic and eukaryotic cells. This transient, short peptide sequence functions like a postal address on an envelope by targeting proteins for secretion or for transfer to specific organelles for further processing. Understanding how signal peptides function is crucial in predicting where proteins are translocated. To support this understanding, we present SPDB signal peptide database http://proline.bic.nus.edu.sg/SPDB, a repository of experimentally determined and computationally predicted signal peptides. Results: SPDB integrates information from two sources (a) Swiss-Prot protein sequence database which is now part of UniProt and (b) EMBL nucleotide sequence database. The database update is semi-automated with human checking and verification of the data to ensure the correctness of the data stored. The latest release SPDB release 3.2 contains 18,146 entries of which 2,584 entries are experimentally verified signal sequences; the remaining 15,562 entries are either signal sequences that fail to meet our filtering criteria or entries that contain unverified signal sequences. Conclusion: SPDB is a manually curated database constructed to support the understanding and analysis of signal peptides. SPDB tracks the major updates of the two underlying primary databases thereby ensuring that its information remains up-to-date.
SPDB: a specialized database and web-based analysis platform for swine pathogens
Database (Oxford) 2020 Jan 1;2020:baaa063.32761141 PMC7409514
The rapid and accurate diagnosis of swine diseases is indispensable for reducing their negative impacts on the pork industry. Next-generation sequencing (NGS) is a promising diagnostic tool for swine diseases. To support the application of NGS in the diagnosis of swine disease, we established the Swine Pathogen Database (SPDB). The SPDB represents the first comprehensive and highly specialized database and analysis platform for swine pathogens. The current version features an online genome search tool, which now contains 26 148 genomes of swine, swine pathogens and phylogenetically related species. This database offers a comprehensive bioinformatics analysis pipeline for the identification of 4403 swine pathogens and their related species in clinical samples, based on targeted 16S rRNA gene sequencing and metagenomic NGS data. The SPDB provides a powerful and user-friendly service for veterinarians and researchers to support the applications of NGS in swine disease research. Database URL: http://spdatabase.com:2080/.
The Relationship between Microstructure and Fracture Behavior of TiAl/Ti2AlNb SPDB Joint with High Temperature Titanium Alloy Interlayers
Materials (Basel) 2022 Jul 12;15(14):4849.35888316 PMC9316006
In this paper, spark plasma diffusion bonding technology was employed to join TiAl and Ti2AlNb with high temperature titanium alloy interlayer at 950 °C/10kN/60 min, then following furnace cooling at cooling rate up to 100 °C/min. After welding, the joint was aging heat-treated at 800 °C for 24 h. The microstructure and the elements diffusion of the TiAl/Ti2AlNb joint was analyzed by field emission scanning electron microscopy (FESEM) with EDS. Moreover, the tensile properties of the joint were tested at room temperature, 650 °C, and 750 °C. The results show that the spark plasma diffusion bonding formed a high quality TiAl/Ti2AlNb joint without microcracks or microvoids, while also effectively protecting the base metal. Significant differences in the microstructure of the joint appeared from TiAl side to Ti2AlNb side: TiAl BM (Base Metal) ↿DP(Duplex) and NG (Near-Gamma) ↿α2-phase matrix with needle-like α-phase ↿bulk α2-phase ↿needle-like α-phase ↿metastable β-phase ↿Ti2AlNb BM. After heat treatment at 800 °C for 24 h, the microstructure of the TiAl side and the interlayer region did not change, but the density and size of the needle-like α-phase in region 3 increased slightly. The microstructure of Ti2AlNb near the weld changed obviously, and a large number of fine O phases are precipitated from the metastable β phase matrix after heat treatment. Except for the Ti2AlN near-interface region, the effect of heat treatment on the microstructure of the joint is not significant. The microhardness of the joint is in the shape of a mountain peak. The maximum microhardness at the interface is above 500 HV, and it is significantly reduced to 400 HV after heat treatment. The fracture of the joint occurred at the interface at room temperature, 650 °C, and 750 °C. with the tensile strength 450 MPa, 540 MPa, and 471 Mpa, respectively, and mainly showing brittle fracture.
Toward the development of smart and low cost point-of-care biosensors based on screen printed electrodes
Crit Rev Biotechnol 2016;36(3):495-505.25578718 10.3109/07388551.2014.992387
Screen printing technology provides a cheap and easy means to fabricate disposable electrochemical devices in bulk quantities which are used for rapid, low-cost, on-site, real-time and recurrent industrial, pharmaceutical or environmental analyses. Recent developments in micro-fabrication and nano-characterization made it possible to screen print reproducible feature on materials including plastics, ceramics and metals. The processed features forms screen-printed disposable biochip (SPDB) upon the application of suitable bio-chemical recognition receptors following appropriate methods. Adequacy of biological and non-biological materials is the key to successful biochip development. We can further improve recognition ability of SPDBs by adopting new screen printed electrode (SPE) configurations. This review covers screen-printing theory with special emphasis on the technical impacts of SPE architectures, surface treatments, operational stability and signal sensitivity. The application of SPE in different areas has also been summarized. The article aims to highlight the state-of-the-art of SPDB at the laboratory scale to enable us in envisaging the deployment of emerging SPDB technology on the commercial scale.
Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation
Mol Pharm 2015 Jun 1;12(6):1703-16.25856201 10.1021/acs.molpharmaceut.5b00175
Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∿.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. The ADC composed of DM4 (N(2')-deacetyl-N(2')-[4-mercapto-4-methyl-1-oxopentyl]maytansine) conjugated to antibody via the N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB) linker was selected for development as SAR3419. A molar ratio for DM4/antibody of between 3 and 5 was selected for the final design of SAR3419. Evaluation of SAR3419 in Ramos tumor xenograft models showed that the minimal effective single dose was about 50 μg/kg conjugated DM4 (∿.5 mg/kg conjugated antibody), while twice this dose gave complete regressions in 100% of the mice. SAR3419 arrests cells in the G2/M phase of the cell cycle, ultimately leading to apoptosis after about 24 h. The results of in vitro and in vivo studies with SAR3419 made with DM4 that was [(3)H]-labeled at the C20 methoxy group of the maytansinoid suggest a mechanism of internalization and intracellular trafficking of SAR3419, ultimately to lysosomes, in which the antibody is fully degraded, releasing lysine-N(ε)-SPDB-DM4 as the initial metabolite. Subsequent intracellular reduction of the disulfide bond between linker and DM4 generates the free thiol species, which is then converted to S-methyl DM4 by cellular methyl transferase activity. We provide evidence to suggest that generation of S-methyl DM4 in tumor cells may contribute to in vivo tumor eradication via bystander killing of neighboring tumor cells. Furthermore, we show that S-methyl DM4 is converted to the sulfoxide and sulfone derivatives in the liver, suggesting that hepatic catabolism of the payload to less cytotoxic maytansinoid species contributes to the overall therapeutic window of SAR3419. This compound is currently in phase II clinical evaluation for the treatment of diffuse large B cell lymphoma.